Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript [Seeking Alpha]
Xilio Therapeutics, Inc. (XLO)
Company Research
Source: Seeking Alpha
Company Participants Ruth du Moulin Rene Russo - President, CEO & Director Katarina Luptakova - Chief Medical Officer Christopher Frankenfield - CFO & COO Conference Call Participants Diwakar Davar Aparna Parikh Daina Graybosch - Leerink Partners LLC, Research Division Marc Frahm - TD Cowen, Research Division Presentation Operator Good afternoon, and thank you for joining Xilio Therapeutics conference call and webcast. [Operator Instructions] I would now like to turn the call over to Ruth du Moulin from Xilio Therapeutics. Please go ahead. Ruth du Moulin Good afternoon, everyone, and thank you for joining today's call to discuss Xilio's key data updates presented at the Society for Immunotherapy of Cancer or SITC conference last week. The press releases reporting the details of our SITC presentation can be found on the Investor Relations section of Xilio's website. Joining today's call from Xilio are Dr. Rene Russo, our President and Chief Executive Offi
Show less
Read more
Impact Snapshot
Event Time:
XLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XLO alerts
High impacting Xilio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
XLO
News
- Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial ResultsGlobeNewswire
- Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingGlobeNewswire
- Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingGlobeNewswire
XLO
Sec Filings
- 12/1/25 - Form 4
- 11/25/25 - Form S-8
- 11/25/25 - Form 4
- XLO's page on the SEC website